Internal Medicine, Rheumatology · Ashland, OR
NPI
1205896115
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1801 Highway 99 N Ste 2
Ashland, OR, 97520
Phone (541) 625-6555
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
215,371 services
Medicare patients, 2024
622
Average age 71
Drug cost, 2024
$4.6M
6,676 prescriptions
Company payments, 2025
$680
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David I Dryland was code J3262 (injection, tocilizumab, 1 mg), 62,580 times for 13 patients. In total David I Dryland billed 215,371 services in 45 codes, and Medicare paid $2.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 62,580 | 13 | $4.49 | $281K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 32,841 | 141 | $0.10 | $3,270 |
| J0491 Injection, anifrolumab-fnia, 1 mg | Office | 30,600 | 11 | $13.29 | $407K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 16,350 | 17 | $9.08 | $148K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 8,976 | 23 | $24.88 | $223K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 5,900 | 16 | $16.21 | $96K |
| Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 5,284 | 17 | $23.37 | $123K |
| J9312 Injection, rituximab, 10 mg | Office | 4,700 | 15 | $57.55 | $270K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,990 | 39 | $0.23 | $455 |
| 99214 Office E&M - Established | Office | 1,055 | 555 | $78.20 | $82K |
| J0897 Injection, denosumab, 1 mg | Office | 960 | 11 | $20.05 | $19K |
| 96415 Chemotherapy Administration | Office | 556 | 70 | $20.80 | $12K |
| J1020 Injection, methylprednisolone acetate, 20 mg | Office | 536 | 57 | $4.32 | $2,317 |
| 96365 Intravenous Infusion, Hydration | Office | 461 | 62 | $47.63 | $22K |
| 96413 Chemotherapy Administration | Office | 376 | 77 | $96.22 | $36K |
By year: 2022 $2.0M for 109,889 services; 2023 $2.1M for 146,411 services; 2024 $2.3M for 215,371 services.
Medicare prescription drug claims, 2024
In 2024, the drug David I Dryland prescribed most often to Medicare patients was Prednisone, with 896 prescriptions and refills. In total David I Dryland wrote 6,676 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 896 | 2,216 | 293 | $10K |
| Methotrexate Methotrexate Sodium | 857 | 2,207 | 265 | $27K |
| Hydroxychloroquine Sulfate Generic | 699 | 1,820 | 213 | $37K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 610 | 610 | 97 | $16K |
| Leucovorin Calcium Generic | 334 | 898 | 108 | $37K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 305 | 305 | 37 | $8,622 |
| Enbrel Sureclick Etanercept | 255 | 292 | 28 | $2.1M |
| Tramadol Hcl Generic | 225 | 225 | 50 | $2,188 |
| Folic Acid Generic | 169 | 500 | 54 | $1,461 |
| Gabapentin Generic | 162 | 385 | 53 | $4,496 |
| Trazodone Hcl Generic | 149 | 407 | 47 | $2,690 |
| Duloxetine Hcl Generic | 105 | 263 | 35 | $3,126 |
| Methylprednisolone Generic | 99 | 111 | 52 | $920 |
| Leflunomide Generic | 94 | 250 | 35 | $8,737 |
| Allopurinol Generic | 94 | 262 | 26 | $1,406 |
Brand drugs: 731 claims; generic drugs: 5,933 claims; opioid claims: 1,232.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David I Dryland $680 ($680 in general payments such as food, travel and fees) from 11 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $132.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 2 | $132 |
| Abbvie Inc. ABBV | 5 | $109 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $99.5 |
| Organon LLC OGN | 3 | $82.41 |
| UCB, Inc. UCB.BR | 3 | $59.35 |
| Janssen Biotech, Inc. JNJ | 2 | $53.1 |
| Celgene Corporation BMY | 1 | $46.1 |
| GlaxoSmithKline, LLC. GSK | 2 | $33.69 |
| Sandoz Inc. SDZ.SW | 1 | $26.56 |
| Amgen Inc. AMGN | 1 | $19.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.